Prempro Osteoporosis Use In Older Women May Be Limited To Second-Line
Executive Summary
Wyeth is considering revising Prempro's indication to more clearly define the hormone therapy as second-line osteoporosis prevention for older women
You may also be interested in...
Hormone Therapy Osteoporosis Approval Hurdle Unchanged By WHI, FDA Says
Hormone therapy drug sponsors seeking approval for osteoporosis do not need to submit to FDA any extraordinary safety data in light of the WHI findings, Metabolic & Endocrine Division Director David Orloff, MD, said Oct. 7
Hormone Therapy Osteoporosis Approval Hurdle Unchanged By WHI, FDA Says
Hormone therapy drug sponsors seeking approval for osteoporosis do not need to submit to FDA any extraordinary safety data in light of the WHI findings, Metabolic & Endocrine Division Director David Orloff, MD, said Oct. 7
Wyeth Prempro Gets Dementia Warning; FDA Considering HRT Class Labeling
FDA is considering hormone replacement therapy class labeling that would incorporate data from a WHI sub-study showing twice the rate of dementia in patients taking Wyeth's Prempro estrogen/progestin combo